Ricardo Carvalho 🇧🇷 (@rcarvalhoonco) header
Ricardo Carvalho 🇧🇷 (@rcarvalhoonco) profile picture

Medical Oncologist at BP Mirante Hospital. Former fellow at @HCBarretos. Focus in GI & GU Cancer. #PancSM #CRCSM #KCSM #GiCSM #GC #PCSM. Tweets are my own

Sao Paulo, Brazil
Joined September 2010
Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)Photo by Ricardo Carvalho 🇧🇷 (@rcarvalhoonco)
Ricardo Carvalho 🇧🇷 retweeted
Lynch syndrome is the most common inherited cancer predisposition syndrome, affecting approximately one in 350–450 people, yet most carriers are undiagnosed. A new Review provides an integrated overview, highlighting advances in diagnosis, prevention, & treatment: spkl.io/60147jGse
1
38
123
10,946
Ricardo Carvalho 🇧🇷 retweeted
Same mutation, different organ, different story. KRAS G12C leads in lung cancer, G12D leads in colorectal cancer, and the same G12C inhibitor behaves very differently in each tissue. The allele alone does not define the strategy. Tissue context does. Which part surprised you most? #KRAS #KRASG12C #KRASG12D #RAS #NSCLC #LungCancer #ColorectalCancer #ColonCancer #CRC #Oncology #PrecisionOncology #PrecisionMedicine #TargetedTherapy #MolecularOncology #CancerResearch #Biomarkers #Genomics #TumorBiology #EGFR #MAPK #Sotorasib #Adagrasib #MedEd #OncologyEducation #MedTwitter #ScienceCommunication #Infographic #HealthcareProfessionals #CancerScience #Oncologist
2
13
1
39
2,230
Ricardo Carvalho 🇧🇷 retweeted
🔥off the press🔥 Overall and line-specific impact of targeted therapies in advanced BTC after chemoimmunotherapy failure @JHepatology doi.org/10.1016/j.jhep.2026.… 👉OS benefit for targeted therapies in 2nd line 👉Early NGS testing @myESMO @ASCO @EASLnews @ILCAnews
12
25
1,521
Ricardo Carvalho 🇧🇷 retweeted
🔥off the press🔥 👍Finally approved by FDA 👉Approval includes patients with or without an identified RAS tumor mutation @myESMO @ASCO
6
19
1,494
Ricardo Carvalho 🇧🇷 retweeted
Outcomes of Y90-radioembolization as downstaging to liver transplantation in pts with HCC and tumoral portal vein thrombosis @HEP_Journal doi.org/10.1097/HEP.00000000… 👉SIRT downstaged 25% of PVTT pts to transplant eligibility 👉Response-adapted subsequent therapy! @myESMO @ASCO @EASLnews @ILCAnews
2
29
71
2,875
Ricardo Carvalho 🇧🇷 retweeted
🚨 dMMR ≠ Lynch syndrome! A crucial distinction every oncologist should know. A new Lancet review highlights the diagnostic pathway: 🔬 MLH1/PMS2 loss? Check BRAF V600E and/or MLH1 methylation. 🧬 MSH2/MSH6 or isolated MSH6/PMS2 loss? Consider germline testing. 🔍 Germline negative? Look for double-somatic MMR alterations. 💡 Key message: Tumour MMR deficiency is a starting point, not a hereditary cancer diagnosis. 📊 Save this diagnostic algorithm! @oncoalert @esmo_open @myesmo @asco #LynchSyndrome #PrecisionOncology Full paper link in comment below ⬇️.
2
83
206
11,732
Ricardo Carvalho 🇧🇷 retweeted
Daraxonrasib (Rasonque), an oral RAS inhibitor from Revolution Medicines, is now approved in Europe for previously treated metastatic pancreatic cancer, regardless of RAS mutation status. The phase 3 RASolute 302 trial showed improved survival compared with chemotherapy. globenewswire.com/news-relea…
12
3
71
3,549
Ricardo Carvalho 🇧🇷 retweeted
🔥off the press🔥 Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study doi.org/10.1016/j.cgh.2026.0… 👉408 pts 👉Tumor burden & AFP at LT associated with HCC recurrence 👉Rejection associated with non-HBV, irAEs, age, shorter ICI washout 🧐pre-LT ICI feasible, clinical utility needs to be established @myESMO @EASLnews @ILCAnews
1
33
2
65
4,903
Ricardo Carvalho 🇧🇷 retweeted
Real-world anti-EGFR rechallenge in ctDNA-profiled mCRC: the REalCHALLENGE study European Journal of Cancer 👉ctDNA WT: ORR 29% vs 0%, DCR 68% vs 42% mPFS 4.7 vs 2.9, mOS 21.9 vs 11.1 mo 🧐support value of molecular profiling to optimize selection for anti-EGFR rechallenge @myESMO @ASCO
1
24
46
2,717
Ricardo Carvalho 🇧🇷 retweeted
Biomarker matched combinations!!
I'd like to share this slide again. We've reached a point where the treatment of PDAC is undergoing a paradigm shift. We're only at the beginning - and we'll see even better data. In my opinion, combination studies are the way forward. Time will tell. $TNGX $RVMD $ERAS
3
5
27
1,938
Ricardo Carvalho 🇧🇷 retweeted
🧪 # — SIERRA, Phase IIIb | Journal of Hepatology Patients with poor prognostic features - Child-Pugh B liver function, ECOG 2, or main-trunk portal vein thrombosis (Vp4) - are routinely excluded from phase III HCC trials. 🎯 This study gave STRIDE (tremelimumab + durvalumab) to 👥 111 patients: Child-Pugh B7/B8 44 · ECOG 2 47 · Vp4 PVTT 20 ⚠️ Grade 3/4 related AEs at 6 mo: 19.8% overall, 25.0% in Vp4 📊 ORR 14.4% overall · ECOG 2 21.3% · Vp4 15.0% 📉 Child-Pugh B ORR only 6.8% This is the patient in clinic every week who was never in HIMALAYA. Toxicity looks manageable across all three cohorts, but the Child-Pugh B response rate of 6.8% is the sobering line - liver reserve still limits what immunotherapy can do. #GIOnc #HCC #LiverCancer pubmed.ncbi.nlm.nih.gov/4283…
5
7
486
Ricardo Carvalho 🇧🇷 retweeted
Look at these curves - 🔥 NICHE-2 at five years - Phase 2 (The Lancet) 🎯 Stage II–III dMMR colon cancer, before surgery 💊 Ipilimumab ×1 + nivolumab ×2, then resection 👥 111 per-protocol patients, six Dutch hospitals ✅ 3-year DFS 100% at a median 58.7 mo ✅ 5-year OS 100% (exploratory) 🩸 ctDNA cleared in 80/97 before surgery, all negative after ⚠️ Single-arm, no comparator The pathological response rates from NICHE-2 were already striking; this is the survival follow-up that tells us they held. Zero recurrences across 111 patients, after only roughly a month of treatment w/o chemo before surgery. The comparison that now matters is with *ATOMIC*, which added atezolizumab to adjuvant FOLFOX after surgery: two routes to curing dMMR colon cancer, one of them with six months of chemotherapy and one without. NICHE-2 is single-arm, so one can say that a randomized comparison is still owed before it replaces surgery-first. #CRC #dMMR thelancet.com/journals/lance…
1
10
15
979
Ricardo Carvalho 🇧🇷 retweeted
NCCN Colon Cancer Guidelines (v3.2026) A reminder: ctDNA is prognostic, but not yet predictive. I've seen a stage I colon cancer patient receive adjuvant CAPOX solely because of positive ctDNA!
4
26
109
5,012
Ricardo Carvalho 🇧🇷 retweeted
🥤 Can starting nutritional supplements EARLY reduce chemoradiotherapy toxicity? 🚨 New RCT in JAMA Oncology (n=216) in nasopharyngeal cancer: 📉 >5% weight loss: 65.4% vs 80.7% (P=.01) 🔥 Grade ≥3 mucositis: 14% vs 26.6% 💰 Potentially lower treatment costs! 💡 Takeaway: Don’t wait for malnutrition to develop. Early nutritional support matters. Should proactive nutrition become routine from Day 1 of CCRT? @oncoalert #Oncology #HeadNeckCancer Full paper link in comment below ⬇️
1
16
1
47
4,047
Ricardo Carvalho 🇧🇷 retweeted
RASOLUTE 303 update 82 locations (expansion from 33 sites in Sept 2026) Expansion to sites in Australia, Austria, Belgium, Brazil, Canada, Germany, Hong Kong, Italy, Japan, The Netherlands, Singapore, South Korea, Spain, Taiwan, United Kingdom FYI: the 21 locations in the US (active not recruiting) Opened March 2026 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Prior Tweet xitter.gq/KRASKickers/status/209…
RASolute 303 international trial: 33 sites: US, Australia, Taiwan UK, Japan, Brazil, Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients W/ Metastatic Pancreatic Adenocarcinoma Phase 3 trial opened Spring 2026 900 patients NCT07491445 more info from @oncodaily oncodaily.com/oncolibrary/ra…
1
4
11
1,036
Ricardo Carvalho 🇧🇷 retweeted
We touched on 5 🔑 GI Malignancy studies from #ESMO26 w/ @MDmanishshah & #EricVanCutsem. Here is the data! ✅ #HERIZONGEA01 ✅ #CLARITYGastric01 ✅ #AZUR1 ✅ #CHECKMATE8HW ✅ #HARMONiGI1 #OncTwitter #gism @OncoAlert @myESMO
GI Malignancies Highlights from #ESMO26 w/ @MDmanishshah & #EricVanCutsem ✅ #HERIZONGEA01 ✅ #CLARITYGastric01 ✅ #AZUR1 ✅ #CHECKMATE8HW ✅ #HARMONiGI1 Full 🗣️ ⭐️ oncbrothers.com/esmogi26 ⭐️“Oncology Brothers” podcast #OncTwitter #gism @OncoAlert @OncUpdates
1
27
1
60
5,160